KPIs & Operating Metrics(New)

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Aquestive Therapeutics (AQST) Asset Writedowns and Impairment (2018 - 2019)

Aquestive Therapeutics has reported Asset Writedowns and Impairment over the past 2 years, most recently at $6000.0 for Q3 2019.

For Q3 2019, Asset Writedowns and Impairment fell 85.71% year-over-year to $6000.0; the TTM value through Sep 2019 reached $16000.0, changed N/A, while the annual FY2018 figure was $53000.0, N/A changed from the prior year.
Asset Writedowns and Impairment for Q3 2019 was $6000.0 at Aquestive Therapeutics, down from $24000.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $42000.0 in Q3 2018 and troughed at -$20000.0 in Q4 2018.